Abstracts tagged "T cells"

Abstract Number: 639 • 2014 ACR/ARHP Annual Meeting
Lack of Response Gene to Complement-32 Impairs Th17 Differentiation and Attenuates Lupus-like Chronic Graft Versus Host Disease
Vinh Nguyen¹, Cosmin Tegla², Cornelia Cudrici³, Tudor Badea⁴, Horea Rus² and Violeta Rus¹, ¹Medicine, University of Maryland School of Medicine and Veteran Affairs Medical Center, Baltimore, MD, ²Neurology, University of Maryland School of Medicine and Veteran Affairs Medical Center, Baltimore, MD, ³Neurology, University of Maryland School of Medicine, Baltimore, MD, ⁴NIH, National Eye Institute, Bethesda, MD
Background/Purpose . Response Gene to Complement (RGC)-32 was cloned and characterized by our group as one of the genes induced by complement activation. It encodes…
Abstract Number: 2728 • 2014 ACR/ARHP Annual Meeting
Reduction of MAIT Cell Frequency Associated with Reduced Cell Proliferation and Enhanced Cell Death in Systemic Lupus Erythematosus
Asako Chiba¹, Naoto Tamura², Eri Hayashi², Ran Matsudaira³, Yoshinari Takasaki⁴ and Sachiko Miyake¹, ¹Immunology, Juntendo University School of Medicine, Tokyo, Japan, ²Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ³Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ⁴Department of Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Mucosal-associated invariant T (MAIT) cells are innate-like lymphocytes which are restricted by the MHC-related molecule-1 (MR1) and express a semi-invariant TCRα chain: Vα7.2-Jα33 in…
Abstract Number: 1752 • 2014 ACR/ARHP Annual Meeting
CD30 As a Target of Aptamers and Delivery Portal for Aptamer-shRNA to Block Th17 Cells
Cong-Qiu Chu¹, Pingfang Song², Yuan K. Chou³ and Shao Tao², ¹Rheumatology, Oregon Health & Science Univ, Portland, OR, ²Oregon Health & Science University, Portland, OR, ³Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR
Background/Purpose Aptamers are single-stranded 20 –100 nucleotides (RNA or DNA) that bind to molecular targets with high affinity and specificity due to their stable three…
Abstract Number: 1541 • 2014 ACR/ARHP Annual Meeting
Distinct Regulation of T Helper Cell Differentiation By Biologic DMARD Therapy in Rheumatoid Arthritis
Shingo Nakayamada¹, Satoshi Kubo¹, Maiko Yoshikawa¹, Naoki Yunoue¹, Yusuke Miyazaki¹, Kazuyoshi Saito¹ and Yoshiya Tanaka², ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: In the pathogenesis of rheumatoid arthritis (RA), T helper cells can differentiate into functionally distinct subsets, leading to the persistent inflammation and immune abnormality…
Abstract Number: 606 • 2014 ACR/ARHP Annual Meeting
The Immunological Basis of the Sex-Bias in Ankylosing Spondylitis: Th17 Expansion Is Restricted to Male Patients and Correlates with Sex-Related Alteration in Vitamin D Metabolism
Eric Gracey^1,2, Blerta Green², Paul Yip³, Renise Ayearst⁴, Ammepa Anton⁵, Aifeng Lin² and Robert D. Inman⁶, ¹Immunology, University of Toronto, Toronto, ON, Canada, ²Genetics and Development, University Health Network, Toronto, ON, Canada, ³Clinical Biochemistry, University Health Network, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵Rheumatology, University Health Network, Toronto, ON, Canada, ⁶Immunlogy and Institute of Medical Science, University of Toronto and Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose : Ankylosing spondylitis (AS) is an inflammatory arthritis of the spine, which has a major impact on function and quality of life. AS is…
Abstract Number: 2727 • 2014 ACR/ARHP Annual Meeting
T Cells Trigger Interstitial Pneumonia in Polymyositis
Akira Takeda^1,2, Yasutsugu Fukushima³, Takaji Matsutani⁴, Yoichiro Haji¹, Chisun Min¹, Ryo Rokutanda¹, Yasuhiro Suyama¹, Mitsumasa Kishimoto⁵, Ken-ichi Yamaguchi¹ and Masato Okada⁶, ¹Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ²Division of Clinical Immunology & Rheumatology, International University of Health and Welfare Hospital, Nasu-shiobara, Japan, ³Department of Pulmonary Medicine and Clinical Immunology, Dokkyo University School of Medicine, Mibu, Japan, ⁴Laboratory of Immune Regulation, Wakayama Medical University, Ibaraki, Japan, ⁵St. Luke's International Hospital, Tokyo, Japan, ⁶Immuno-Rheumatology Center, St. Luke's International Hospital, tokyo, Japan
Background/Purpose: The lung is frequently affected in connective tissue diseases (CTDs). Polymyositis (PM) is a major CTD characterized by idiopathic inflammatory lesions of muscle and…
Abstract Number: 1751 • 2014 ACR/ARHP Annual Meeting
CD4 Aptamer-RORγt shRNA Chimera Inhibits IL-17 Synthesis By Human CD4⁺ T cells
Cong-Qiu Chu¹, Pingfang Song², Yuan K. Chou³, Xiaowei Zhang², Roberto Meza-Romero², Kentaro Yomogida³ and Gil Benedek², ¹Rheumatology, Oregon Health & Science Univ, Portland, OR, ²Oregon Health & Science University, Portland, OR, ³Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR
Background/Purpose RNA interfering (RNAi)-mediated gene silencing holds great promise for manipulating T cells to study basic T cell biology and for developing potential T cell…
Abstract Number: 1495 • 2014 ACR/ARHP Annual Meeting
Preclinical and Clinical Phase I Profile of MK-8457, a Selective Spleen Tyrosine Kinase and Zeta-Chain-Associated Protein Kinase 70 Inhibitor, Developed for the Treatment of Rheumatoid Arthritis
Gene Marcantonio¹, Alan Bass², Gretchen Baltus³, Judith Boice¹, Hongmin Chen⁴, Michael Crackower⁵, Jeroen Elassaiss-Schaap⁶, Michael Ellis⁷, Tomoko Freshwater⁸, Francois Gervais⁹, Jane Guo¹⁰, Sammy Kim⁹, Lily Moy⁵, Alan Northrup⁷, Jie Zhang-Hoover⁴, Mathew Maddess¹¹, Richard Miller¹², Marcella Ruddy⁵, Stella Vincent¹³, Haoling Weng¹ and Hani Houshyar¹⁴, ¹Merck & Co., Whitehouse Station, NJ, ²Safety Assessment, Merck & Co., Boston, MA, ³Immunomodulatory Regulators, Merck & Co., Boston, MA, ⁴Pharmacology, Merck & Co., Boston, MA, ⁵Merck & Co., Boston, MA, ⁶Clinical PK-PD, Merck & Co., Oss, Netherlands, ⁷Medicinal Chemistry, Merck & Co., Boston, MA, ⁸PPDM Early Stage, Merck & Co., Rahway, NJ, ⁹Cell Pathways and Proteins, Merck & Co., Boston, MA, ¹⁰Immunology, Merck & Co., Boston, MA, ¹¹Discovery Process Chemistry, Merck & Co., Boston, MA, ¹²Biochemistry & Biophysics, Merck & Co., Boston, MA, ¹³PPDM Preclinical ADME, Merck & Co., Boston, MA, ¹⁴33 Avenue Louis Pasteur, Merck & Co., Boston, MA
Background/Purpose: Spleen tyrosine kinase (SYK) is a potential target for treatment of several diseases including rheumatoid arthritis. SYK is a member of the Zeta-chain-associated protein…
Abstract Number: 397 • 2014 ACR/ARHP Annual Meeting
Th9 Lymphocytes in Rheumatoid Arthritis
Rossella Talotta¹, Angela Berzi², Fabiola Atzeni¹, Donata Dell'Acqua¹, Piercarlo Sarzi-Puttini¹ and Daria Trabattoni², ¹Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, ²Chair of Immunology, Department of Biomedical and Clinical Sciences “L. Sacco, Milan, Italy
Background/Purpose Th9 cells are IL-9-secreting Th lymphocytes that are involved in the immunological responses underlying parasitic infections and allergic diseases. In the case of autoimmune…
Abstract Number: 2726 • 2014 ACR/ARHP Annual Meeting
CD28null T Cells from Polymyositis Patients Are Cytotoxic to Autologous Muscle Cells in Vitro Via Perforin-Dependent Mechanisms
Jayesh Pandya¹, Paulius Venalis¹, Lubna Al-Khalili², Mohammad Shahadat Hossain¹, Ingrid E. Lundberg¹, Vivianne Malmström¹ and Andreas E. R. Fasth¹, ¹Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ²Division of Industrial Biotechnology, KTH - Royal Institute of Technology, Stockholm, Sweden
Background/Purpose: Inflammatory infiltrates of muscles in polymyositis are dominated by CD4+CD28null and CD8+CD28null T cells. In contrast to conventional CD28+ T cells, these cells…
Abstract Number: 1749 • 2014 ACR/ARHP Annual Meeting
Molecular Mechanisms Underlying 1,25(OH)₂D₃-Mediated Suppression of Th17 Cell Activity
Wendy Dankers^1,2, Jan Piet van Hamburg^2,3, Wida Razawy^1,2, Nadine Davelaar^1,2, Anne-Marie Mus^1,2, Patrick Asmawidjaja^1,2, Johannes van Leeuwen⁴, Edgar Colin⁵ and Erik Lubberts^1,2, ¹Rheumatology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ²Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ³Rheumatology, Erasmus MC, Rotterdam, Netherlands, ⁴Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁵Rheumatology, ZGT, Almelo, Netherlands
Background/Purpose Vitamin D has suppressive effects on autoimmune diseases, such as rheumatoid arthritis (RA). Within these diseases, Th17 cells play a crucial role in the…
Abstract Number: 1465 • 2014 ACR/ARHP Annual Meeting
Follicular Helper T Cells Control Autoimmunity through IL-21/IL-21 Receptor Interaction in RA Patients
Shikha Singla¹, Minzi Chen², Jerry Pounds Jr.², Omar Khan², Jerald M. Zakem², Kismet Collins², Tamika Webb-Detiege², William E. Davis², Robert Quinet² and Xin Zhang³, ¹Rheumatology, Ochner Medical Center, New Orleans, LA, ²Rheumatology, Ochsner Medical Center, New Orleans, LA, ³Institute of Translational Research, Ochsner Medical Center, New Orleans, LA
Background/Purpose Rheumatoid Arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the synovium, causing progressive joint destruction and reduction in quality of life…
Abstract Number: 366 • 2014 ACR/ARHP Annual Meeting
Soluble 4-1BB Is a Marker of Joint Involvement and Disease Activity in Rheumatoid Arthritis
Morten Aagaard Nielsen¹, Thomas Andersen², Kristian Stengaard-Pedersen³, Kim Hoerslev-Petersen⁴, Merete Lund Hetland⁵, Peter Junker⁶, Mikkel Ostergaard⁷, Malene Hvid¹ and Bent Deleuran⁸, ¹Department of Biomedicine, Aarhus University, Aarhus, Denmark, ²Dept. of Biomedicine, Aarhus University, Aarhus, Denmark, ³Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁴Rheumatology, Research Unit at King Christian X Hospital for Rheumatic Diseases, Graasten, Denmark, ⁵DANBIO, Center for Rheumatology and Spine Diseases, Glostrup University Hospital, Glostrup, Denmark, Glostrup, Denmark, ⁶University of Southern Denmark, Odense, Denmark, ⁷Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ⁸Dept. of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose 4-1BB is induced on T cells after antigen encounter and promotes clonal expansion and accumulation of high numbers of antigen-specific effector-type T cells primarily…
Abstract Number: 3003 • 2014 ACR/ARHP Annual Meeting
Am80 Ameliorates Bleomycin-Induced Dermal Fibrosis By Suppressing the Pro-Fibrotic Phenotype of Fibroblasts, Endothelial Cells, and Immune Cells
Tetsuo Toyama¹, Yoshihide Asano¹, Takehiro Takahashi¹, Ryosuke Saigusa¹, Yohei Ichimura¹, Takashi Taniguchi¹, Shinji Noda¹, Kaname Akamata¹, Shinichi Sato¹, Takafumi Kadono¹ and Koichi Shudo², ¹Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ²Reseach Foundation ITSUU Laboratory, Tokyo, Japan
Background/Purpose: Am80 is a synthetic retinoid serving as an agonist for retinoic acid receptor α/β with chemical and pharmacological advantages over all-trans retinoic acid, such…
Abstract Number: 2724 • 2014 ACR/ARHP Annual Meeting
Deficiency of Ro52/TRIM21 in Different Subsets of Peripheral Blood Mononuclear Cells from Patients with Inflammatory Myopathies
Angeles Shunashy Galindo-Feria¹, Diana Gómez-Martín², Ana Barrera-Vargas², Javier Merayo-Chalico¹ and Jorge Alcocer-Varela², ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: The detection of Ro52/TRIM21 autoantibodies has been considered an independent prognostic marker in different rheumatic conditions. However, the information about the expression of Ro52/TRIM21…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].